Porta Sophia Files Third-Party Preissuance Submission for GH RESEARCH IRELAND LIMITED U.S. Patent Application 18/851,322

MADISON, WI USA (November 14, 2025) Porta Sophia filed a third-party preissuance submissions with the United States Patent and Trademark Office (USPTO) today for U.S. Pat. App. Ser. No. 18/851,322 entitled “5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF POSTPARTUM DEPRESSION”, which is currently assigned to GH RESEARCH IRELAND LIMITED. The submissions consisted of 14 prior art documents that are material to the patentability of all 47 claims of the application. Porta Sophia, a non-profit psychedelic prior art library, leverages the experience of legal and interdisciplinary academic scholars to promote an ethical psychedelic patenting landscape that preserves the integrity of the public domain. The organization curates and makes relevant historical documentation readily available for anyone wanting to explore the scope of psychedelic technologies, including patent examiners.  

Patent application: 5-MeO-DMT for treatment of Postpartum Depression (PPD) 

The ’322 application was filed on September 26, 2024. It claims methods of treating PPD with 5-MeO-DMT administered intravenously, intramuscularly, or subcutaneously, including in treatment-resistant cases and patients with suicidal ideation. The application also covers measurements of baseline severity defined by using standard depression scales (e.g., MADRS or HAM-D), alongside evidence of reduced maternal functioning (e.g., BIMF). Dosing may involve a single administration or a titrated series, with subsequent doses escalated until a peak psychedelic experience is achieved as assessed by common questionnaires (e.g., MEQ30, ASC, or a peak-experience scale). Efficacy is evaluated by rapid improvement on global clinical measures (e.g., CGI-S) shortly after dosing and around the following day. The claims also cover known breastfeeding guidance and improvement in maternal functioning. 

Prior art in the third-party preissuance submission included U.S. and international patent documents and a peer reviewed journal article. This prior art anticipates claims in the ’322 application. The full third-party submission documentation is available here. 

Third-party submissions of prior art 

United States patent law allows third parties to submit prior art and concise descriptions of their relevance to the USPTO. Documents submitted may be considered in the examination of that patent application. In addition, these submissions have a broad impact because applicants have a duty to disclose the prior art submitted against a single patent application for other relevant patent applications filed by the applicant. 

Porta Sophia tracks and analyzes psychedelic patent applications globally. If an application improperly claims innovation of something known in the public domain and meets the standards of Porta Sophia's third party intervention evaluation criteria, the team assembles evidence against these invalid claims and contests them directly to the relevant patent office through third-party interventions.